Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512007 | 0.92 | MAPK1 (0.31) | FAAHMGLLMAPK1 | |
| SCHEMBL20625499 | 0.91 | LPL (0.31) | — | |
| SCHEMBL26132129 | 0.88 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL31334888 | 0.87 | SIGMAR1 (0.37) | SIGMAR1 | |
| SCHEMBL31705089 | 0.86 | SIGMAR1 (0.35) | FAAHMGLLSIGMAR1ACKR3 | |
| SCHEMBL26134119 | 0.85 | MAPK1 (0.31) | MAPK1 | |
| SCHEMBL16372532 | 0.84 | MEN1 (0.34) | — | |
| SCHEMBL1534508 | 0.77 | CD274 (0.35) | — | |
| SCHEMBL17004842 | 0.74 | USP30 (0.48) | MAPK1 | |
| SCHEMBL17918656 | 0.72 | FAAH (0.40) | FAAHMGLLSIGMAR1MAPK1ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | FAAH 1871/4885MGLL 579/4885SIGMAR1 2098/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | FAAH 1851/4885MGLL 879/4885SIGMAR1 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.